Indications
Yorvipath is a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism
Composition
- Active substance
- palopegteriparatide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Yorvipath
- Active substance
- palopegteriparatide
- ATC code
- H05AA
- Therapeutic area
- Hypoparathyroidism
- Marketing authorisation holder
- Ascendis Pharma Bone Diseases A/S
- Status
- Authorised
- EU authorisation
- 17 Nov 2023